Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ginsenoside composition for treating cardiovascular and cerebrovascular diseases

A technology of cardiovascular and cerebrovascular diseases and ginsenoside, which is applied in the field of medicine, can solve the problems of difficult determination of content, complex components, low content, etc., and achieve the effect of improving various injuries, exact drug effect, and inhibiting anticoagulant effect

Active Publication Date: 2013-04-10
KUNMING PHARMA GRP JINTAIDE PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The components of Panax notoginseng saponins are complex. Currently known and used as quality control indicators are mainly ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, ginsenoside Rd and notoginsenoside R1. It is difficult to determine its content, and due to the difference of Panax notoginseng medicinal materials and the different preparation processes of various manufacturers, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, ginsenoside Rd, notoginseng saponin R1 and others in different batches of Panax notoginseng saponins The content of rare saponins has different degrees of difference and different proportions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginsenoside composition for treating cardiovascular and cerebrovascular diseases
  • Ginsenoside composition for treating cardiovascular and cerebrovascular diseases
  • Ginsenoside composition for treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1, the effect of ginsenoside Rg1, ginsenoside Rb1 and their ratio on ADP-induced platelet aggregation in rabbits in vitro

[0029] 1 drug

[0030] 1.1 Test drug preparation

[0031] Before the experiment, distilled water was used to prepare a solution with a high concentration of 3.5700 mg / ml, a medium concentration of 1.7850 mg / ml, and a low concentration of 0.8925 mg / ml as the final concentration. The different ratio solutions of ginsenoside Rg1 and ginsenoside Rb1 were prepared according to Ginsenoside Rg1 and ginsenoside Rb1 are mixed in different volume proportions of the above-mentioned concentrations. The normal control group used normal saline, wherein 30 μl of Tween was added to every 10 ml of each dose of the test drug and normal saline. The above test drugs were prepared into clear solutions before in vitro administration.

[0032] 1.2 Reagents

[0033]Adenosine diphosphate (ADP): product of Sigma Company; Sodium citrate: Tianjin Chemical Reage...

Embodiment 2

[0064] Example 2 Ginsenoside Rg 1 with Rb 1 Effects of Different Proportions on Specific Myocardial Hypoxia Resistance Model

[0065] 1. Test material:

[0066] Drug: Ginsenoside Rg 1 Ginsenoside Rb 1 Prepare Rg1:Rb1=1:4, 4:1, 1:1 (W / W) mixture respectively; Panax notoginseng saponins, produced by Kunming Pharmaceutical Group Co., Ltd., content 93%, batch number: 20080115; 0.9% chlorinated Sodium injection, produced by Kunming Nanjiang Pharmaceutical Co., Ltd., batch number: 080530h 1 .

[0067] Reagents and equipment: isoproterenol hydrochloride injection (2ml: 1mg Shanghai Hefeng Pharmaceutical Co., Ltd.), 250ml ground-mouth jar, timer, soda lime vaseline, etc.

[0068] Experimental animals: SPF grade ICR mice, ♀ Combined use, W: 18~22g, produced by the laboratory animal laboratory of Kunming Pharmaceutical Group Co., Ltd., production license number: SCXK (Dian) 2009-0001; use license number: SYXK (Dian) 2009-0001.

[0069] 2 Test method:

[0070] The mice were ran...

Embodiment 3

[0078] Example 3: Effects on collagen-epinephrine-induced thrombus formation in mice

[0079] 1 test material

[0080] Drug: Ginsenoside Rg 1 Ginsenoside Rb 1 Prepare Rg1:Rb1=1:4, 4:1, 1:1 (W / W) mixture respectively; Panax notoginseng saponins, produced by Kunming Pharmaceutical Group Co., Ltd., content 93%, batch number: 20080115; 0.9% chlorinated Sodium injection, produced by Kunming Nanjiang Pharmaceutical Co., Ltd., batch number: 080530h 1 . Bayer Aspirin is produced by Bayer Corporation of the United States.

[0081] Reagents: collagen, epinephrine, etc.

[0082] Experimental animals: SPF grade ICR mice, ♀ Combined use, W: 18~22g, produced by the laboratory animal laboratory of Kunming Pharmaceutical Group Co., Ltd., production license number: SCXK (Dian) 2009-0001; use license number: SYXK (Dian) 2009-0001.

[0083]2 Test method:

[0084] 60 mice were randomly divided into 8 groups: Rg1:Rb1 (5:1) group, Rg1:Rb1 (4:1) group, Rg1:Rb1 (1:1), Rg1:Rb1 (1:4), Rg1: Rb...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of medicine, and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, wherein the pharmaceutical composition comprises a ginsenoside monomer Rg1 and a ginsenoside monomer Rb1, a weight ratio of the Rg1 to the Rb1 is 1:4-4:1. The ginsenoside composition of the present invention has the following advantages that:the pharmaceutical composition of the present invention has effects of blood activating and stasis removing, blood circulation promoting and collateral activating, and can be applicable for obstruction of collaterals by blood stasis, apoplectic hemiplegia, chest stuffiness and pains, and central retinal vein occlusion; the efficacy of the pharmaceutical composition is definite; the adverse reaction rate is significantly reduced; when the weight ratio of the Rg1 to the Rb1 is 1:4, the LD50 of the ginsenoside composition is more than 1000 mg / kg, and is significantly higher than the LD50 of panax notoginsenosidum; the ginsenoside composition provides the significant inhibition effect for thrombosis, and the anticoagulant effect so as to essentially improve various damages of ischemic cardiovascular and cerebrovascular disease patients due to ischemia.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a ginsenoside monomer Rg 1 ginsenoside monomer Rb 1 A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. Background technique [0002] Cardiovascular and cerebrovascular diseases are the primary diseases that threaten human health, and are the diseases that cause the most death and disability. Cardiovascular and cerebrovascular diseases account for more than 50% of deaths. About 4 million people die from this disease every year in our country, one person dies from this disease every 24 seconds, and one person becomes disabled every 13 seconds, accounting for 40% of the total death causes in our country. According to the forecast of the World Health Organization, by 2020, non-communicable diseases will account for 79% of the causes of death in my country, among which cardiovascular diseases will take the first place. Cardiovascular and cerebrovascular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P9/00A61P9/10A61P7/04A61P7/02
Inventor 龚云麒刘一丹杨旭娟高宏涛刘国光
Owner KUNMING PHARMA GRP JINTAIDE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com